Report Overview
Report Summary
Bile duct connects the liver to the gallbladder and carries bile, which is synthesized by the liver and stored in the gallbladder. The main function of bile is breakdown of fat during digestion. Bile duct cancer is commonly known as cholangiocarcinoma. The specific cause of bile duct cancer is unknown, but few factors that cause bile duct cancer are long-term inflammation in the liver, biliary stones, abnormalities in bile duct such as cysts, infection with liver fluke parasites leading to bile duct leading to cancer, and exposure to harmful chemicals or toxins. Major symptoms associated with bile duct cancer include jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever. Some drugs used to treat bile duct cancer include 5-fluorouracil (5-fu), gemcitabine, cisplatin, capecitabine and oxaliplatin.
In 2020, the global Bile Duct Cancer Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2027, with a CAGR of xx% during 2021-2027.
This report focuses on the global Bile Duct Cancer Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bile Duct Cancer Drugs development in United States, Europe and China.
The key players covered in this study
Celgene
Mylan
Eli Lilly
Johnson & Johnson
Accord Healthcare
Roche
Teva
AbbVie
Bristol-Myers Squibb
Pfizer
Intercept Pharmaceuticals
Novartis
Sanofi
Kyowa Hakko Kirin
Delcath Systems
Fresenius Kabi
Market segment by Type, the product can be split into
5-Fluorouracil (5-FU)
Gemcitabine
Cisplatin
Capecitabine
Oxaliplatin
Others
Market segment by Application, split into
Hospitals & Clinic
Cancer Treatment Centers
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Bile Duct Cancer Drugs status, future forecast, growth opportunity, key market and key players.
To present the Bile Duct Cancer Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Bile Duct Cancer Drugs are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table Of Contents
Table Of Contents
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Bile Duct Cancer Drugs Market Size Growth Rate by Type (2017-2027)
1.4.2 5-Fluorouracil (5-FU)
1.4.3 Gemcitabine
1.4.4 Cisplatin
1.4.5 Capecitabine
1.4.6 Oxaliplatin
1.4.7 Others
1.5 Market by Application
1.5.1 Global Bile Duct Cancer Drugs Market Share by Application (2017-2027)
1.5.2 Hospitals & Clinic
1.5.3 Cancer Treatment Centers
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Bile Duct Cancer Drugs Market Size
2.2 Bile Duct Cancer Drugs Growth Trends by Regions
2.2.1 Bile Duct Cancer Drugs Market Size by Regions (2017-2027)
2.2.2 Bile Duct Cancer Drugs Market Share by Regions (2017-2020)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Bile Duct Cancer Drugs Market Size by Manufacturers
3.1.1 Global Bile Duct Cancer Drugs Revenue by Manufacturers (2017-2020)
3.1.2 Global Bile Duct Cancer Drugs Revenue Market Share by Manufacturers (2017-2020)
3.1.3 Global Bile Duct Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Bile Duct Cancer Drugs Key Players Head office and Area Served
3.3 Key Players Bile Duct Cancer Drugs Product/Solution/Service
3.4 Date of Enter into Bile Duct Cancer Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Bile Duct Cancer Drugs Market Size by Type (2017-2020)
4.2 Global Bile Duct Cancer Drugs Market Size by Application (2017-2020)
5 United States
5.1 United States Bile Duct Cancer Drugs Market Size (2017-2020)
5.2 Bile Duct Cancer Drugs Key Players in United States
5.3 United States Bile Duct Cancer Drugs Market Size by Type
5.4 United States Bile Duct Cancer Drugs Market Size by Application
6 Europe
6.1 Europe Bile Duct Cancer Drugs Market Size (2017-2020)
6.2 Bile Duct Cancer Drugs Key Players in Europe
6.3 Europe Bile Duct Cancer Drugs Market Size by Type
6.4 Europe Bile Duct Cancer Drugs Market Size by Application
7 China
7.1 China Bile Duct Cancer Drugs Market Size (2017-2020)
7.2 Bile Duct Cancer Drugs Key Players in China
7.3 China Bile Duct Cancer Drugs Market Size by Type
7.4 China Bile Duct Cancer Drugs Market Size by Application
8 Japan
8.1 Japan Bile Duct Cancer Drugs Market Size (2017-2020)
8.2 Bile Duct Cancer Drugs Key Players in Japan
8.3 Japan Bile Duct Cancer Drugs Market Size by Type
8.4 Japan Bile Duct Cancer Drugs Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Bile Duct Cancer Drugs Market Size (2017-2020)
9.2 Bile Duct Cancer Drugs Key Players in Southeast Asia
9.3 Southeast Asia Bile Duct Cancer Drugs Market Size by Type
9.4 Southeast Asia Bile Duct Cancer Drugs Market Size by Application
10 India
10.1 India Bile Duct Cancer Drugs Market Size (2017-2020)
10.2 Bile Duct Cancer Drugs Key Players in India
10.3 India Bile Duct Cancer Drugs Market Size by Type
10.4 India Bile Duct Cancer Drugs Market Size by Application
11 Central & South America
11.1 Central & South America Bile Duct Cancer Drugs Market Size (2017-2020)
11.2 Bile Duct Cancer Drugs Key Players in Central & South America
11.3 Central & South America Bile Duct Cancer Drugs Market Size by Type
11.4 Central & South America Bile Duct Cancer Drugs Market Size by Application
12 International Players Profiles
12.1 Celgene
12.1.1 Celgene Company Details
12.1.2 Company Description and Business Overview
12.1.3 Bile Duct Cancer Drugs Introduction
12.1.4 Celgene Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.1.5 Celgene Recent Development
12.2 Mylan
12.2.1 Mylan Company Details
12.2.2 Company Description and Business Overview
12.2.3 Bile Duct Cancer Drugs Introduction
12.2.4 Mylan Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.2.5 Mylan Recent Development
12.3 Eli Lilly
12.3.1 Eli Lilly Company Details
12.3.2 Company Description and Business Overview
12.3.3 Bile Duct Cancer Drugs Introduction
12.3.4 Eli Lilly Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.3.5 Eli Lilly Recent Development
12.4 Johnson & Johnson
12.4.1 Johnson & Johnson Company Details
12.4.2 Company Description and Business Overview
12.4.3 Bile Duct Cancer Drugs Introduction
12.4.4 Johnson & Johnson Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.4.5 Johnson & Johnson Recent Development
12.5 Accord Healthcare
12.5.1 Accord Healthcare Company Details
12.5.2 Company Description and Business Overview
12.5.3 Bile Duct Cancer Drugs Introduction
12.5.4 Accord Healthcare Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.5.5 Accord Healthcare Recent Development
12.6 Roche
12.6.1 Roche Company Details
12.6.2 Company Description and Business Overview
12.6.3 Bile Duct Cancer Drugs Introduction
12.6.4 Roche Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.6.5 Roche Recent Development
12.7 Teva
12.7.1 Teva Company Details
12.7.2 Company Description and Business Overview
12.7.3 Bile Duct Cancer Drugs Introduction
12.7.4 Teva Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.7.5 Teva Recent Development
12.8 AbbVie
12.8.1 AbbVie Company Details
12.8.2 Company Description and Business Overview
12.8.3 Bile Duct Cancer Drugs Introduction
12.8.4 AbbVie Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.8.5 AbbVie Recent Development
12.9 Bristol-Myers Squibb
12.9.1 Bristol-Myers Squibb Company Details
12.9.2 Company Description and Business Overview
12.9.3 Bile Duct Cancer Drugs Introduction
12.9.4 Bristol-Myers Squibb Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.9.5 Bristol-Myers Squibb Recent Development
12.10 Pfizer
12.10.1 Pfizer Company Details
12.10.2 Company Description and Business Overview
12.10.3 Bile Duct Cancer Drugs Introduction
12.10.4 Pfizer Revenue in Bile Duct Cancer Drugs Business (2017-2020)
12.10.5 Pfizer Recent Development
12.11 Intercept Pharmaceuticals
12.12 Novartis
12.13 Sanofi
12.14 Kyowa Hakko Kirin
12.15 Delcath Systems
12.16 Fresenius Kabi
13 Market Forecast 2021-2027
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2021-2027)
13.10 Market Size Forecast by Application (2021-2027)
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details